S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllers

CD8-mediated virus inhibition can be detected in HIV-1+ subjects controlling virus replication in the absence of ART. Characterizing the CD8⁺ T cells that mediate virus inhibition is important for determining the nature of CD8⁺ T cells that need to be elicited by an HIV-1 vaccine.

We used a 3-day CD8⁺ T cell mediated virus inhibition assay (CD8 VIA) to assess CD8⁺ function. Primary CD4⁺ enriched lymphocytes were infected with reporter viruses expressing transmitted/founder envelopes in the presence of serial dilutions of autologous CD8⁺ T cells. We examined activated CD8⁺ T cells from 22 HIV-1+ subjects (of which 15 were virus controllers (VC)), 37 HIV-1 vaccinees (DNA prime, rAd5 boost encoding HIV-1 Env and Gag-Pol) and 6 seronegative donors. Phenotypic analysis of HIV-1 specific CD8⁺ cells was determined by 13 color flow cytometry. Phenotypically-defined CD8⁺ T cell subsets from selected donors were sorted by flow cytometry and tested for virus suppression.

VCs had robust antiviral activity against both transmitted/founder and NL4-3 enveloped viruses (1.43 +/- 0.67 log reduction). Among vaccinees, CD8 VIA correlated with HIV-1 specific CD107a expression; and weakly with IFN-gamma expression. No correlations were observed with CD8⁺ cell expression of IL-2, TNF-alpha, or MIP-1 beta. Virus inhibition by sorted cells was absent from naive CD8⁺ T cells; the predominant activity was from central and early effector memory populations.

CD8-mediated virus inhibition, as measured in a 3-day assay with early transmitted reporter viruses, was present in HIV-1+ subjects and vaccinees. Among HIV-1+ subjects, the activity was most robust in virus controllers. Virus suppression correlates most strongly with CD107a, and may come primarily from central memory populations. These data provide insight into the mechanisms of viral inhibition, and suggest that functional analyses of CD8⁺ T cell mediated virus inhibition could identify benchmarks for successful T-cell directed vaccine strategies.

Affiliations

1. DHVI and Surgery, Duke University Medical School, Durham, USA
   • SA Freel
2. ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
   • PK Chattopadhyay
   •  & M Roederer
3. Immunology Core Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
   • L Lamoreaux
   • , D Zarkowsky
   •  & RA Koup
4. Duke University Medical Center; DHVI and Surgery, Durham, NC, USA
   • RG Overman
5. Department of Medicine, University of Alabama, Birmingham, AL, USA
   • C Ochsenbauer-Jambor
   •  & JC Kappes
6. Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
   • CK Cunningham
7. Duke University Medical Center; DHVI and Medicine, Durham, NC, USA
   • TN Denny
8. Duke University Medical Center; DHVI, Immunology and Surgery, Durham, NC, USA
   • KJ Weinhold
9. Department of Surgery, Duke University Medical Center, Durham, NC, USA
   • G Ferrari
10. Viral Pathogenesis Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
    • BS Graham
11. DHVI, Immunology, and Medicine, Duke University Medical Center, Durham, NC, USA
    • BF Haynes
12. Duke University Medical Center, DHVI, Surgery and Immunology, Durham, NC, USA
    • GD Tomaras

Corresponding author

Correspondence to SA Freel.

Reprints and Permissions